Professor Gabrani’s research focuses on cancer therapeutics, molecular virology, and antimicrobial resistance with a strong translational orientation aimed at solving critical healthcare challenges. A major thrust of her work involves the design of combinatorial therapies for cancer, particularly glioblastoma multiforme, one of the most aggressive brain tumors. She has developed and patented a combination therapy involving temozolomide and D-limonene, which has demonstrated improved therapeutic efficacy and holds promise for better clinical outcomes.

In addition to cancer therapeutics, her research investigates plant-derived bioactive compounds for their antimicrobial and anticancer properties. Employing computational biology and bioinformatics, she systematically identifies and characterizes these compounds, enabling the discovery of novel therapeutic agents. Her work also extends to antimicrobial peptides and the identification of novel molecular targets for infectious diseases, contributing to efforts against antimicrobial resistance.

Professor Gabrani has published over 100 peer-reviewed research articles and contributed to several book chapters. She holds two patents, and a successful Technology Transfer to the Industry, reflecting the real-world impact of her work. Her collaborations with national partners bring a multidisciplinary approach to her projects, enhancing both scope and applicability.

Through her research, Professor Gabrani continues to advance scientific understanding, foster innovation, and contribute to healthcare solutions with tangible societal benefits.